a. Patients who have received more than 3000 cGy CNS irradiation. 
b. Patients who have received more than 2000 cGy to mediastinum or liver. 
c. Patients who have received irradiation at lower doses than stated above but 
who developed symptoms of excessive toxicity to normal tissue. [Note: these 
patients may be eligible for protocol #526]. 
C. Eligibility criteria for therapy with HIV-specific T. 
1. HIV-seropositive transplant recipients who have entered study and for whom HIV- 
specific CD8 + T c clones have been generated, expanded in vitro, and transduced with 
the HyTK retrovirus will be eligible for reinfusion of autologous HIV-specific T cells 
beginning following engraftment (ANC > 750/mm 3 ) and discontinuation of 
prophylactic acyclovir. [Note: Patients treated on this protocol will receive Acyclovir 
until ANC > 500/mm 3 and not until day 150 as outlined in protocol #526.] 
2. Patients requiring therapy with acyclovir or ganciclovir [See Section 6.H: Prophylaxis 
and management of herpes virus infections] after initiation of T cell infusions will be 
monitored by PCR analysis of PBL for retroviral vector DNA to determine if 
transferred T cells are eradicated [See Section 6.E.3]. These patients will be eligible 
to receive repeat infusions of non-transduced HIV-specific T c clones to the dose level 
of transduced T cells administered if no toxicity was observed following the initial 
infusions. 
3. Patients requiring zidovudine discontinuation due to toxicity (Section 6.F.3) will 
remain eligible to receive HIV-specific T c therapy. 
4. Signed informed consent that fulfills Institutional Review Board guidelines must be 
obtained for infusion of autologous HIV-specific CD8 + T c clones. 
D. Exclusion criteria for therapy with HIV-specific T, 
1 . ' Recipients who have grade 3 or 4 regimen-related toxicity in any organ system or 
grade 3 or 4 GVHD at the scheduled time of T cell infusion will not be eligible for T 
cell therapy until organ dysfunction has improved and GVHD has resolved to < 
grade 2. 
2. T cell therapy will not be initiated in patients receiving therapy with acyclovir or 
ganciclovir for active herpes virus infections until these infections are resolved and 
antiviral therapy discontinued. 
Treatment Plan 
A. Preparative Regimen 
The preparative regimen for HIV positive patients with lymphoma will be identical to the 
regimen used at the FHCRC (outlined in protocol 164.2) for HIV seronegative patients with 
lymphoma. The treatment plan includes: 
1 . Start allopurinol (200 mg/m 2 /day in three divided doses) on admission and discontinue 
on day -1 (day 0 is the day of transplant). 
2. Chemotherapy 
a. All patients will be treated with CY 60 mg/kg x 2 (calculated on lean body 
weight for obese patients). Patients may be considered for alternative 
chemotherapy for the following reasons: 
1. Patients with previous history of severe CY-induced cystitis. 
[618] 
Recombinant DNA Research, Volume 15 
